On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.'s principal accounting officer, replacing Lisa Peraza, the Company's current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the Effective Date). Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | +6.76% | -0.33% | +76.47% |
May. 07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.47% | 423M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024